Cardiovascular Atlas
About
Menu

SECURE

A European trial in adults aged 65 or older who had had a heart attack in the previous 6 months and had at least one further risk condition. 2499 patients were randomized to a once-daily polypill combining three heart medicines or to usual care. Over a median of 36 months, the polypill group had fewer major cardiovascular events. Patients in the polypill group reported better adherence, and adverse events were similar between groups.

Also called Secondary Prevention of Cardiovascular Disease in the Elderly Trial

  • Study
  • In this atlas

Overview

Design
Randomized, parallel-group, open-label (masking none in the registry) phase 3 trial of a polypill-based strategy against usual care for secondary prevention after a myocardial infarction. The registry records the primary purpose as prevention.
Phase
Phase 3
Enrolled
  • 2,499 participants (enrolled count) (Secondary Prevention of Cardiovascular Disease in the Elderly Trial, retrieved )
  • 2,499 patients (randomized count) (Polypill Strategy in Secondary Cardiovascular Prevention, retrieved )
Sponsor
Not recorded
Funder
Not recorded
Registry
  • NCT NCT02596126
Started
(Secondary Prevention of Cardiovascular Disease in the Elderly Trial, retrieved )
Primary completion
(actual) (Secondary Prevention of Cardiovascular Disease in the Elderly Trial, retrieved )
Completion
(actual) (Secondary Prevention of Cardiovascular Disease in the Elderly Trial, retrieved )
Results first posted
(actual) (Secondary Prevention of Cardiovascular Disease in the Elderly Trial, retrieved )
Countries
Czechia, France, Germany, Hungary, Italy, Poland, Spain (Secondary Prevention of Cardiovascular Disease in the Elderly Trial, retrieved )
Care setting
Trial sites in seven European countries (Spain, Italy, Germany, France, Hungary, Poland and the Czech Republic), per the registry description. (Secondary Prevention of Cardiovascular Disease in the Elderly Trial, retrieved )
Registry status
  • “COMPLETED” (U.S. National Library of Medicine (ClinicalTrials.gov), retrieved )

Technical summary

Trial (NCT02596126) whose registry lead sponsor is Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III (accents removed here), registry phase 3, randomized, parallel, masking none, primary purpose prevention. Sites in seven European countries. The abstract counts 2499 randomized with group denominators of 1237 and 1229; the sources do not explain the difference. The registry holds results posted 2025-05-23, which this record does not extract. Numbers are on the claim. Only the PubMed abstract and the registry record were read.

Arms

  • Cardiovascular polypill

    Intervention Cardiovascular polypill

    A once-daily polypill with three heart medicines, taken by mouth (registry); the doses and contents are on the polypill page.

  • Usual care

    Intervention None named

    Standard secondary-prevention therapy per European guidelines, with drugs and doses at the discretion of the treating physicians (registry).

Findings

No findings are published for this study.

Record details

Record id
cardio:secure-trial
Content hash
7b84e3e97d94c50da49a4ea7fd8f32c0a73ee216f214936cb86cc5feeb8c2648